Levetiracetam Kensington (Levetiracetam)

• Levetiracetam is used to manage epileptic seizure disorders by modulating neuronal excitability.
• Partial‑onset seizures: decreases the number of focal seizure events and may improve seizure control when added to existing therapy.
• Generalized tonic‑clonic seizures: provides adjunctive therapy to lower the incidence of convulsive seizures in patients with refractory epilepsy.
• Myoclonic seizures: helps suppress sudden, brief muscle jerks, contributing to better overall seizure management in appropriate clinical settings.
• Adjunctive therapy for epilepsy: employed alongside other antiepileptic drugs to achieve comprehensive seizure control when monotherapy is insufficient.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing synaptic transmission and reducing excessive neuronal firing. By decreasing the release of excitatory neurotransmitters, the drug lowers neuronal hyperexcitability that underlies various seizure types, without directly affecting ion channels or G‑protein pathways. The precise mechanism remains under investigation, but the SV2A binding is considered central to its antiepileptic efficacy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of lightheadedness or unsteadiness.
• Fatigue: feeling unusually tired or lacking energy.
• Headache: mild to moderate head pain.
• Irritability: increased mood swings or agitation.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Mood changes: depression, suicidal thoughts, or severe anxiety.
• Hematologic abnormalities: low blood cell counts such as neutropenia or thrombocytopenia.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust dose or monitor renal function in patients with reduced kidney clearance.
• Pregnancy: category B, use only if benefits outweigh potential risks; discuss with obstetrician.
• Psychiatric history: monitor for worsening mood or behavioral changes, especially in patients with prior depression or anxiety.
• Concomitant CNS depressants: use caution as additive sedation may occur.
• Drug interactions: review all current medications for potential interactions (see interaction section).
• Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Levetiracetam has a relatively low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma levels, compromising efficacy.
• Phenobarbital: can decrease levetiracetam concentrations, necessitating dose adjustment.

Moderate Interactions (Monitor Closely)

• Valproic acid: may increase levetiracetam levels, monitor for toxicity.
• Opioids (e.g., tramadol): additive CNS depression may occur.
• Alcohol: combined use can enhance sedation and dizziness.